Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPM502 in celiac disease
NCT05660109Phase 2Completed
- Sponsor
- Topas Therapeutics
- Start
- Dec 2022
- Primary completion
- Jul 2024
- Modality
- Nanoparticles
- Countries
- 6
01
Overview
A Phase 2 trial of TPM502 in celiac disease, sponsored by Topas Therapeutics. Started Dec 2022; status: completed.
02
Drugs
TPM502
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT05660109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660109.